Press Releases & Company News

Disclosure of shareholdings

Lainate, Italy – June 21, 2007 – Based on Art. 24 of the Articles of Association of Cosmo Pharmaceuticals SpA, Lainate (SWX: COPN), the company has received the following notice from one of its main shareholders:

The Hopp family, consisting of Dietmar and Oliver Hopp respectively their investment companies DH-CAPITAL GmbH & Co KG and OH Beteiligungen GmbH & Co KG, inform that they in total now hold 1’476’874 shares (10.6% of all votes) out of a total of 13'875'000 shares.

About Cosmo Pharmaceuticals
Cosmo is a speciality pharma company that aims to become a global leader in optimised therapies for certain gastrointestinal diseases. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as ulcerative colitis and Crohn’s disease, and colon infections. Cosmo’s first MMX™ product that has reached the market is LIALDA™ / MEZAVANT™, a treatment for IBD that is licensed globally to Giuliani and Shire Pharmaceuticals. Cosmo’s proprietary MMX™ technology is at the core of the company’s product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. For further information on Cosmo, please visit the Company’s website: www.cosmopharmaceuticals.com

Contact:
Dr. Chris Tanner, CFO und Head of Investor Relations
Cosmo Pharmaceuticals SpA
Tel: +39 02 9333 7614

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

Most computers will open PDF documents automatically, but you may need to download Adobe Reader.